Cargando…

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved patients’ outcomes and paved the way for the beginning of advent of targeted approaches in breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, Thuy, Claret, Francois X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376449/ https://www.ncbi.nlm.nih.gov/pubmed/22720269 http://dx.doi.org/10.3389/fonc.2012.00062

Ejemplares similares

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer
por: La Ferla, Marco, et al.
Publicado: (2019)

Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer
Publicado: (2019)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
por: Sayan, Mutlay, et al.
Publicado: (2019)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
por: Liu, Xiaoyun, et al.
Publicado: (2022)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Trastuzumab-Induced Interstitial Pneumonitis
por: Errisuriz, Kimberly, et al.
Publicado: (2023)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
por: Nami, Babak, et al.
Publicado: (2018)

Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis
por: Yu, Zhou, et al.
Publicado: (2017)

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
por: Ninio-Many, Lihi, et al.
Publicado: (2020)

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
por: Díaz-Redondo, Tamara, et al.
Publicado: (2019)

Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
por: Roukos, Dimitrios H.
Publicado: (2009)

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient
por: Wu, Junyi, et al.
Publicado: (2022)

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary
por: Giarratano, Tommaso, et al.
Publicado: (2018)

Non-Genomic Actions of Estrogens on the DNA Repair Pathways Are Associated With Chemotherapy Resistance in Breast Cancer
por: Jiménez-Salazar, Javier E., et al.
Publicado: (2021)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
por: Xu, Zhi-qiao, et al.
Publicado: (2017)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
por: Padmanabhan, Regina, et al.
Publicado: (2022)

ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report
por: Takayasu, Hirokazu, et al.
Publicado: (2023)

Editorial: The molecular mechanisms of metastasis and therapeutic resistance in breast cancer
por: Liang, Yuanke, et al.
Publicado: (2023)

Editorial: Update of Current Evidences in Breast Cancer Surgery
por: Franceschini, Gianluca, et al.
Publicado: (2022)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression
por: Yu, Ling, et al.
Publicado: (2022)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
por: Wang, Haoqi, et al.
Publicado: (2022)

Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research
por: Lin, Hsiang-Wen, et al.
Publicado: (2023)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
por: Wong, Andrea L. A., et al.
Publicado: (2012)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
por: Kong, Xiangyi, et al.
Publicado: (2019)

HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review
por: Chen, Min-long, et al.
Publicado: (2023)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

MicroRNAs as Therapeutic Targets in Nasopharyngeal Carcinoma
por: Wang, Sumei, et al.
Publicado: (2019)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
por: Shang, Mao, et al.
Publicado: (2022)

Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study
por: Ginzac, Angeline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_havhaeobujm9sq94rd34mlgkjc